Download PDF
Digestive Disease Interventions 2019; 03(01): 046-051
DOI: 10.1055/s-0039-1688517
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Embolotherapy for Neuroendocrine Tumors

Gregory J. Nadolski
2   Division of Interventional Radiology, Department of Radiology, Penn Image-Guided Interventional Laboratory, University of Pennsylvania, Philadelphia
,
Michael C. Soulen
1   Division of Interventional Oncology, Department of Radiology and Surgery, Abramson Cancer Center, University of Pennsylvania, Philadelphia
› Author Affiliations
Further Information

Publication History

10 November 2018

10 February 2019

Publication Date:
22 April 2019 (online)

Also available at
   Buy Article Permissions and Reprints
Zoom Image

Correction to:

Embolotherapy for Neuroendocrine TumorsDigestive Disease Interventions 2019; 03(01): e1-e1
DOI: 10.1055/s-0039-1683939

Abstract

The most frequent solid organ involved in metastatic neuroendocrine tumors (NET) is the liver. Hepatic metastases occur during the lifetime of 46% to 93% of patients with NETs. Intra-arterial embolotherapies are palliative and should be used for patients with unresectable disease not amenable to resection or ablation. The most widely accepted indications for liver embololization for NET metastases are progression of unresectable hepatic metastases threatening liver function and palliation of hormone-related symptoms uncontrolled by somatostatin analogues. This article will discuss patient selection and administration of all embolotherapies currently used for palliation of neuroendocrine liver metastases.

Keywords

Neuroendocrine Tumors - hepatic metastases - embolotherapy